183 career peer-reviewed research publications. 85 in the past 5 years.

Aaron SD, Vandemheen K, FitzGerald JM, et al.  Reevaluation of Diagnosis in Adults with Physician-Diagnosed Asthma.  JAMA 317(3):269-279, 2017.

Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 304 (19): 2145-2153, 2010.

Aaron SD, Vandemheen K, Boulet LP, et al. Over-diagnosis of asthma in obese and non-obese adults. CMAJ 179(11): 1121-1131, 2008.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol or fluticasone/salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Annals of Internal Medicine 146 (8):545-555, 2007.

Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Yozghatlian V, Bye P, Bell S, Chan F, Rose B, Jeanneret A, Stephenson A, Noseworthy M, Freitag A, Paterson N, Doucette S, Harbour C, Ruel M, MacDonald M. Combination Antibiotic Susceptibility Testing to Treat Exacerbations of Cystic Fibrosis Associated with Multi-Resistant Bacteria: A Randomized, Double-Blind, Controlled Clinical Trial. The Lancet 366: 463-71, 2005.

Aaron SD, Vandemheen K, Hebert P, Dales R, Stiell I, Ahuja J, Dickinson G, Brison R, Rowe B, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. The New England Journal of Medicine 348, 2618-25, 2003. 

All Other Publications

1)    Yaghoubi M, Adibi A, Zafari Z, FitzGerald J, Aaron SD, Johnson K, Sadatsafavi M.  Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States.  J Allergy Clin Immunol,  2019 Dec 11. pii: S0091-6749(19)31634-3. doi: 10.1016/j.jaci.2019.11.038, in press.  
 2)    Shah A, Ayas N, Tan W, Malhotra A, Kimoff J, Kaminska M, Aaron SD, Jen R.  Sleep Quality and Nocturnal Symptoms in a Community-Based COPD Cohort.  J of Chron Obstr Pulm Dis https://doi.org/10.1080/15412555.2019.1695247, 2020.  
 3)    Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, Gula L, Ha A, Healey JS, Inoue Y, Judson MA, Juneau D, Kusano K, Quinn R, Rivard L, Toma M, Varnava A, Wells G, Wickremasinghe M, Kron J.  Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT).  Am Heart J 2019 Oct 20;220:246-252. doi: 10.1016/j.ahj.2019.10.003. [Epub ahead of print]  
4)    Bourbeau J, Bhutani M, Hernandez P, Aaron SD, et al.  Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence.  Can J Resp Crit Care Sleep Med, https://doi.org/10.1080/24745332.2019.1668652, 2019.  
5)    Guanzhang J, Maclagen L, To T, Aaron SD, Yao Z, Gershon A.  Smoking and smoking cessation among people with chronic obstructive pulmonary disease.  Can J Resp Crit Care Sleep Med, https://doi.org/10.1080/24745332.2019.1692259, 2019.   6)    Barrecheguren M, Pinto L, Seyed-Mohammad Y, Tan W, Li PZ, Aaron SD, et al.  Identification and definition of asthma-COPD overlap: the CanCOLD study. Respirology, in press.  
7)    Adibi A, Sin D, Safari A, Johnson K, Aaron SD, FitzGerald JM, Sadatsafavi M. The Acute COPD Exacerbation Prediction Tool (ACCEPT): development and external validation of a personalized prediction model.   In press, Lancet Resp Med.  
8)    Tan W, Bourbeau J, Aaron SD, Hogg J, et al.  The effects of marijuana smoking on lung function in older people.  European Resp J 54:1900826; 2019.  
 9)    Luc F, Prieur E, Whitmore GA, Gibson P, Vandemheen K, Aaron SD (senior author).  Placebo Effects in Clinical Trials Evaluating Patients with Uncontrolled Persistent Asthma.  Annals of The American Thoracic Society, 16(9):1124-1130, 2019. 
10) Kendzerska T, Aaron SD, To T, Licskai C, et al.  Effectiveness and Safety of Inhaled Corticosteroids in Elderly Individuals with Chronic Obstructive Pulmonary Diseases (COPD) and/or Asthma: A Population-Based Study.  Annals of The American Thoracic Society 16(10):1252-1262, 2019.  
11) Stanojevic S, Sykes J, Stephenson A, Aaron SD, Whitmore G.  Development and External Validation of 1- and 2- year Mortality Prediction Models in Cystic Fibrosis.  European Resp J, 54: 1900224; DOI: 10.1183/13993003.00224-2019.  
12) Shorofsky M, Bourbeau J, Kimoff J, Jen, R, Malhotra A, Ayas N, Tan W, Aaron SD, et al.  Impaired Sleep Quality in COPD is Associated with Exacerbations: The CanCOLD cohort study.  Chest 156(5):852-863, 2019.  
13) Johnston A, Smith C, Zheng C, Aaron SD, Kelly S, Skidmore B, Wells G.  Influence of prolonged treatment with omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria. Clinical & Experimental Allergy 49(10):1291-1305, 2019.  
14) Aaron SD.  COPD exacerbations: current controversies.  Barcelona Respiratory Network Reviews 5(4):263-76, 2019.  
15) Gershon A, Thiruchelvam D, Aaron SD, et al.  Socioeconomic status and 30-day hospital readmissions for chronic obstructive pulmonary disease: a population-based cohort study. PLOS One, 2019 May 21;14(5):e0216741. doi: 10.1371/journal.pone.0216741.  
16) Gershon A, Mecredy GC, Aaron SD, Camp P, Tu K, Hernandez P, To T. Development of quality indicators for Chronic Obstructive Pulmonary Disease (COPD): a modified RAND Appropriateness Method.  Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 3(1): 30-38, 2019.  
17) Paine N, Bacon S, Bourbeau J, Tan W, Lavoie K, Aaron SD, et al.  Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study. Respiratory Medicine 146 (1): 1-9, 2019.  
18) Criner GJ, Martinez FJ, Aaron SD, et al.  Current Controversies in Chronic Obstructive Pulmonary Disease: A Report from the GOLD Scientific Committee.  Annals of The American Thoracic Society 16(1): 29-39, 2019.  
19) Kendzerska T, Leung RS, Aaron SD, Ayas N, Sandoz J, AS. Cardiovascular outcomes and all-cause mortality in patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease (Overlap Syndrome).  Annals of The American Thoracic Society 16(1):71-81, 2019.  
20) Maras, D., Balfour, L., Tasca, G.A., Gaudet, E., Aaron, SD., Cameron, W.D., Pakhale, S. (2018). Greater breathlessness catastrophizing relates to poorer quality of life in adults living with cystic fibrosis. The Journal of Cystic Fibrosis Jan;18(1):150-157, 2019.  
21) Clinical validation of a risk scale for serious outcomes among COPD patients managed in the emergency department.  Stiell IG, Perry J, Clement C, Brison R, Rowe B, MD, Aaron SD, McRae A, Borgundvaag B, Calder L, Forster A, Brinkhurst J, Wells GA.  CMAJ December 03, 2018 190 (48) E1406-E1413; DOI: https://doi.org/10.1503/cmaj.180232, 2018.  
22) Kim V, Aaron SD (senior author).  What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement.  European Resp J, 2018; 52: 1801261 [https://doi.org/10.1183/ 13993003.01261-2018].  
23) Diab N (medical resident), Gershon A, Sin D, Tan W, Bourbeau J, Boulet LP, and Aaron SD (senior author).  Under-diagnosis and over-diagnosis of chronic obstructive pulmonary disease.  The American Journal of Respiratory and Critical Care Medicine 198(9):1130-1139, 2018.  
24) Villa-Roel C, Borgundvaag B, Majumdar SR, Emond M, Campbell S, Sivilotti M, Abu-Laban RB, Stiell IG, Aaron SD, Ambikaipakan S, Rowe BH. Reasons and Outcomes for Patients Receiving ICS/LABA Agents Prior To, And One Month After, Emergency Department Presentations for Acute Asthma. J Asthma 56(9):985-994, 2019.  
25) Aaron SD, Boulet LP, Reddel H, Gershon A.  Under-diagnosis and over-diagnosis of asthma.  The American Journal of Respiratory and Critical Care Medicine 198 (8); 1012–1020, 2018.  
26) Dean BW (medical student), Birnie EE, Whitmore GA, Vandemheen KL, Boulet LP, FitzGerald JM, Ainslie M, Gupta S, Lemiere C, Field SK, McIvor RA, Hernandez P, Mayers I, and Aaron SD (senior author).  Between-Visit Variability in FEV1 as a Diagnostic Test for Asthma in Adults.  Annals of The American Thoracic Society 15(9); 1039–1046, 2018.  
27) Ma KA, Kahn SR, Akaberi A, Dennie C, Rush C, Granton JT, Anderson D, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Hernandez P, Aaron SD, Pena E, Abikhzer G, Hirsch AM; ELOPE Study group.  Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study.  Res Pract Thromb Haemost 17;2(4):670-677, 2018.  
28) Gershon A, Maclagan L, Luo J, To T, Kendzerska T, Stanbrook M, Bourbeau B; Etches J, and Aaron SD (senior author).  End of Life Strategies among Patients with Advanced Chronic Obstructive Pulmonary Disease (COPD).  The American Journal of Respiratory and Critical Care 198(11); 1389–1396, 2018.  
29) Jin, M, Lee E, Ra S, Fishbane N, Tam S, Criner G, Woodruff P, Lazarus S, Albert R, Connett J, Han M, Martinez F, Aaron SD, Reed R, Man S, Leung J, Sin D.  The Relationship of Absolute Telomere Length with Quality of Life, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.  Chest;154(2):266-273, 2018.   30) Cowan J, Mulpuru S, Aaron SD, et al.  Study protocol: a randomized, double blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations.  Pilot and Feasibility Studies, 11;4:135. doi: 10.1186/s40814-018-0327-z, 2018  
31) Gershon, A, Thiruchelvam D, Chapman K, Aaron SD, Stanbrook M, Bourbeau J, Tan W, To T.  Health services burden of undiagnosed and overdiagnosed COPD. Chest 153(6):1336-1346, 2018.  
32) Filho F, Ra S, Mattman A, Schellenberg R, Aaron SD (co-senior author), Reed R (co-senior author), Sin D (co-senior author).   Serum IgG Subclass Levels and Risk of Exacerbations and Hospitalizations in Patients with COPD.   Resp Research Feb 14;19(1):30. doi: 10.1186/s12931-018-0733-z, 2018.  
33)  Poureslami I, Pakhale S, Lavoie K, Gupta S, Bacon S, Aaron SD, To T, Boulet LP, FitzGerald JM.  Patients as research partners in chronic obstructive pulmonary disease and asthma research: Priorities, challenges and recommendations from asthma and COPD patients.  Can J Resp Crit Care Sleep Med 2(3); 138-146, 2018.   34) Vozoris NT, Wang X, Austin PC, O'Donnell DE, Aaron SD, To TM, Gershon AS. Incident diuretic drug use and adverse respiratory events among older adults with COPD.  Br J Clin Pharmacol, 84(3):579-589, 2018.  
35) Tan W, Bourbeau J, Zhou G, Aaron SD, Maltais F, et al.  Global Initiative for Chronic Obstructive Lung Disease 2017 Classification and Lung Function Decline in Chronic Obstructive Pulmonary Disease.  The American Journal of Respiratory and Critical Care Medicine 197(5):670-673, 2018.  
36) Washko GR, Coxson HO, O’Donnell D, and Aaron SD.  CT Imaging of Chronic Obstructive Pulmonary Disease: Insights, Disappointments, and Promise.  Lancet Respir Med 5; 903–908, 2017.  
37) Bourbeau J, Bhutani M , Hernandez P , Marciniuk D , Aaron SD , Balter M, et al.  CTS position statement: Pharmacotherapy in patients with COPD - An update.  Can J Resp Crit Care Sleep Med, 1(4); 222–24, 2017.  
38) Filho F, Ra S, Mattman A, Schellenberg R, Aaron SD (co-senior author), Reed R (co-senior author), Sin D (co-senior author).   Serum Immunoglobulin G and Risk of Exacerbations and Hospitalizations in COPD.  J Allergy Clin Immun, 140; 1164-1167, 2017.  
39) Hegagi M, Aaron SD, James P, Goel R, Chatterjee A.  Increased Prevalence of Colonic Adenomas in Patients with Cystic Fibrosis.  J of Cystic Fibrosis Nov;16(6):759-762, 2017.  
40) De Sousa Sena R, Ahmed, S, Tan W, Li PZ, Labonte L, Aaron SD, et al.  Work Productivity Loss in Mild to Moderate COPD: Lessons Learned from CanCOLD study.  European Resp J, Sep 12;50(3). pii: 1701154. doi: 10.1183/13993003.01154, 2017.   41) Gershon A, MacDonald E, Luo J, Austin P, Gupta S, Sivjee K, Upshur R, Aaron SD.  Concomitant pulmonologist and primary care for chronic obstructive pulmonary disease: a population study.  Family Practice, 16;34(6):708-716, 2017.  
42) Chin M, Aaron SD, Bell SC.  The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis.  Presse Med May 30. pii: S0755-4982(17)30218-X. doi: 10.1016/j.lpm.2016.11.030, 2017.  
43) Won Ra S, Sze MA, Eun CL, Tam S, Aaron SD, Reed RR, Man SF, Sin D.  Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori.  Respiratory Research 18:109, 2017.  
44) Duffy S, Marron R, Voelker H, Albert R, Connett J, Aaron SD, Sin D, Criner G.  Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).  Respiratory Research 18(1):124, DOI 10.1186/s12931-017-0609-7, 2017.  
45) Kahn SR, Akaberi A, Granton JT, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Hirsch AM.  Quality of Life, Dyspnea and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study.  Am J Med, Aug;130(8):990.e9-990.e21. doi: 10.1016/j.amjmed.2017.03.033, 2017.  
46) Ma K, Kahn SR, Hirsch AM, Akaberi A, Anderson DR, Wells PS, Rodger M, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Granton JT.  N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study.  Thromb Res,153:47-49, 2017.  
47) Kendzerska T, Sadatsafavi M, Aaron SD, To T, Lougheed D, FitzGerald JM, Gershon AS.  Concurrent Physician-Diagnosed Asthma and Chronic Obstructive Pulmonary Disease: A Population Study of Prevalence, Incidence and Mortality.  PLOS One, Mar 16;12(3):e0173830. doi: 10.1371/journal.pone.0173830, 2017.  
48) Stephenson A, Sykes J, Berthiaume Y, Singer L, Aaron SD, Whitmore G, Stanojevic S.  .A Clinical Tool to Calculate Post-Transplant Survival Using Pre-Transplant Clinical Characteristics in Adults with Cystic Fibrosis.  Clinical Transplantation, Jun; 31(6).doi: 10.1111/ctr.12950, 2017.  
49) Aaron SD, Tan W, Bourbeau J, Sin D, Loves R, MacNeil J, Whitmore GA.  Diagnostic Instability and Reversals of COPD Diagnosis in Subjects with Mild to Moderate Airflow Obstruction.  The American Journal of Respiratory and Critical Care Medicine 196(3): 306-314, 2017.  
50) Aaron SD, Vandemheen K, FitzGerald JM, et al.  Reevaluation of Diagnosis in Adults with Physician-Diagnosed Asthma.  JAMA 317(3):269-279, 2017.  
51) Kahn SR, Hirsch AM, Akaberi A, Anderson DR, Aaron SD, Granton TJ.  Functional and exercise limitations after a first episode of pulmonary embolism: Results of the ELOPE prospective cohort study. Chest 151(5):1058-1068, 2017.  
52) Lacasse Y, Bernard S, Sériès F, Nguyen VH, Bourbeau J, Aaron SD, Maltais F. Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial. BMC Pulm Med Jan 9;17(1):8. doi: 10.1186/s12890-016-0343-9, 2017.  
53) Bourbeau J, Aaron SD, Barnes N, Davis K, Lacasse Y, Nadeau G.  Evaluating the risk of pneumonia with inhaled corticosteroids in COPD: Retrospective database studies have their limitations.  Respiratory Med, 123; 94-97, 2017.  
54) Stiell IG, Perry J, Clement C, Brison R, Rowe B, Aaron SD, McRae A et al.  Prospective and explicit clinical validation of the Ottawa Heart Failure Risk Scale with and without use of quantitative NT-proBNP.  Acad Emerg Med 24; 316-327, 2017.   55) Gershon A, Mecredy G, Croxford R, To T, Stanbrooke M, Aaron SD.  Outcomes of patients with chronic obstructive pulmonary disease diagnosed with or without pulmonary function testing.  CMAJ, 189(14):E530-E538, 2017.  
56) Tavakoli H, FitzGerald JM, Chen W, Lynd L, Kendzerska T, Aaron S, Gershon A, Marra C, Sadatsafavi M.  Ten-year trends in direct costs of asthma: a population-based study.  Allergy, 72(2):291-299, 2017.  
57) Kendzerska T, To T, Aaron SD, et al. The Impact of a History of Asthma on Long-Term Outcomes of People with Newly Diagnosed Chronic Obstructive Pulmonary Disease: A Population Study.  J Allergy Clin Immunol, 139(3):835-843, 2017.  
58) Aaron SD, Gershon A, Gao C, Yang J, Whitmore GA.  Influence of Country-Level Differences on COPD Prevalence.  Int J COPD, 11: 2305-2313, 2016.   
59) MacNeil J, Loves R, Aaron SD (senior author).  Addressing the misdiagnosis of asthma in adults:  where does it go wrong?  Expert Review of Resp Med, Oct 8:1-12, 2016.  
60) Tan WC, Hague CJ, Leipsic J, Bourbeau J, Zheng L, Li PZ, Sin DD, Coxson HO, Kirby M, Hogg JC, Raju R, Road J, O'Donnell DE, Maltais F, Hernandez P, Cowie R, Chapman KR, Marciniuk DD, FitzGerald JM, Aaron SD.  Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.  PLoS One Nov 18;11(11):e0166745, 2016  
61) Gupta N, Pinto L, Benedetti A, Li P, Tan W, Aaron SD, Chapman K, et al. The COPD Assessment Test: Can it discriminate across COPD subpopulations?  Chest 150(5): 1069-1079, 2016.  
62) Gershon A, Hwee J, Chapman K, Aaron SD, O’Donnell D, et al.  Factors Associated with Undiagnosed and Overdiagnosed COPD.  European Resp J 48(2):561-4, 2016.  
63) Leung JM, Hollander Z, Chen V, Dai D, Tebbutt S, Aaron SD, et al.  COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry.  PLOS ONE DOI:10.1371/journal.pone.0161129, August 15, 2016.  
64) Huus KE, Joseph J, Zhang L, Aaron SD, Mah TF, and Sad S.  Clinical isolates of Pseudomonas aeruginosa from chronically infected cystic fibrosis patients fail to activate the inflammasome during both stable infection and pulmonary exacerbation.  J Immunology, Apr 1;196(7):3097-3108, 2016.   
65) Pakhale S, Baron J, Armstrong M, Tasca G, Gaudet E, Aaron SD, Cameron W, Balfour L. Lost in translation? How adults living with Cystic Fibrosis understand treatment recommendations from their healthcare providers, and the impact on adherence to therapy.  Patient Education and Counseling 99(8):1319-24, 2016.  
66) Labonté LE, Tan WC, Li Z, Mancino P, Aaron SD, et al.  Undiagnosed COPD Contributes to the Burden of Health Care Utilization: Data from the CanCOLD Study.  Am J Resp Crit Care Med, 194(3):285-98, 2016.  
67) Flume P, VanDevanter D, Morgan E, Dudley M, Loutit JS, Aaron SD, Conrad D, Geller DE, Elborn JS.  A Phase 3, Multi-center, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levofloxacin Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients.  Journal of Cystic Fibrosis, 15(4):495-502, 2016.  
68) Sadatsafavi M, Tavakoli H, Kendzerska T, Gershon A, To T, Aaron SD, FitzGerald JM.  History of asthma in patients with chronic obstructive pulmonary disease: a comparative study of economic burden.  Annals of the American Thoracic Society, 13(2):188-96, 2016.  
69) De Matteis S, Iridoy A, Aaron SD, Swann A, Cullinan P.  A new spirometry-based algorithm to predict occupational pulmonary restrictive impairment.  Occupational Med J, 2016 Jan;66(1):50-3.  
70) Chin M, Earlam K, Aaron SD (senior author).  Survival in cystic fibrosis; Trends, Clinical Factors, and Prediction Models.  Pediatric Allergy, Immunology and Pulmonology, 28(4): 244-249, 2015.  
71) Cowan J, Gaudet L, Mulpuru S, Corrales-Medina V, Hawken S, Cameron C, Aaron SD, Cameron DW.  A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.  PLOS ONE DOI:10.1371/journal.pone.0142205, 2015.  
72) Freschi L, Jeukens J, Kukavica-Ibrulj I, Boyle B, Aaron SD, et al.  Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium.  Frontiers in Microbiology 6:1036. doi: 10.3389/fmicb.2015.01036, 2015.   73) Tan W, Bourbeau J, Hernandez P, Chapman K, Aaron SD.  Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study.  Thorax, 70(9):822-829, 2015.  
74) Mulpuru S (master’s student), Aaron SD (senior author), Ronksley P, Lawrence N, Forster AJ.  Hospital Resource Utilization and Patient Outcomes Associated with Respiratory Viral Testing in Hospitalized Patients. Emerging Infectious Diseases 21(8): 1366-71, 2015.  
75) Stephenson AL,  Sykes J, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, Stanojevic S.  Clinical and Demographic Factors Associated with Post-lung Transplantation Survival In Individuals with Cystic Fibrosis: A National Cohort Study.  J Heart Lung Transplant, 34(9):1139-45, 2015.  
76) Alvarez G, Van Dyk D, Desjardins M, Yasseen A, Aaron SD, Cameron DW, et al.  The feasibility, accuracy and impact of Xpert® MTB/RIF testing in a remote Aboriginal community in Canada.  Chest, 148(3):767-73, 2015.  
77) Pakhale S, Baron J, Armstrong M, Tasca G, Gaudet E, Aaron SD, Cameron W, Balfour L.  A cross-sectional study of the psychological needs of adults living with cystic fibrosis.  PLoS ONE, Jun 23;10(6):e0127944. doi: 10.1371, 2015.  
78) Stacey D, Vandemheen K, Henessey R, Aaron SD (senior author).  Implementation of a cystic fibrosis lung transplant referral patient decision aid in routine clinical practice: An observational study.  Implementation Science 7;10(1):17 DOI 10.1186/s13012-015-0206-4, 2015.  
79) Pakhale S, Baron J, Dent R, Vandemheen K, Aaron SD (senior author).  Effects of weight loss on airway responsiveness in obese asthmatics: Does weight loss lead to reversibility of asthma?  Chest, 147(6):1582-90, 2015.  
80) Stephenson A, Tom M, Berthiaume Y, Singer L, Aaron SD, Whitmore GA, Stanojevic S.  A Contemporary Survival Analysis of Individuals with Cystic Fibrosis: A Cohort Study.  Eur Respir J 45:3, 670-679, 2015.   
81) Aaron SD, Stephenson A, Cameron DW, Whitmore GA.  A statistical model to predict one year risk of death in patients with cystic fibrosis.  J Clin Epidemiol 68(11):1336-1345, 2015.  
82) Elborn J, Gelber D, Conrad D, Aaron SD, et al.  A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of Levofloxacin Inhalation Solution (APT-1026) versus Tobramycin Inhalation Solution in Stable Cystic Fibrosis Patients.  Journal of Cystic Fibrosis, 14: 507-514, 2015.  
83) Chin M (respirology resident), De Zoysa M, Slinger R, Aaron SD (senior author).  Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations.  Journal of Cystic Fibrosis, 14: 482-489, 2015.  
84) Srour N, Chaparro C, Vandemheen K, Singer L, Keshavjee S, Aaron SD (senior author).  Impact of infection with transmissible strains of Pseudomonas aeruginosa on lung transplantation outcomes in patients with cystic fibrosis.  J Heart Lung Transplantation, 34(4):588-93, 2015.  
85) Rowe B, Villa-Roel C, Majumdar S, Abu-Laban R, Aaron SD, et al.  Rates and Correlates of Relapse Following Emergency Department Discharge for Acute Asthma: A Canadian 20-Site Prospective Cohort Study.  Chest, 147(1):140-9, 2015.  
86) Alvarez G, Van Dyk D, Davies N, Aaron SD, Cameron DW, et al.  The feasibility of the Interferon Gamma Release Assay and predictors of discordance with the tuberculin skin test for the diagnosis of latent tuberculosis infection in a remote Aboriginal community.  PLOS One, 2014 Nov 11;9(11):e111986. doi: 10.1371/journal.pone.0111986.  
87) Aaron SD.  State of the Art- Management and Prevention of Exacerbations of COPD.  BMJ ; 349: g5237, doi: 10.1136/bmjg5237, 2014.  
88) Criner, G. J., Connett, J. Aaron, SD, Albert, R., Bailey, W., Casaburi, R., Cooper, A., Curtis, J.L., Dransfield, M., Han, M., Make, B., Marchetti, N., Martinez, F. J., Niewoehner, D., Scanlon, P., Sciurba, F., Scharf, S., Sin, D., Voelker, H., Washko, G., Woodruff, P., and Lazarus, S.  Simvastatin for the Prevention of Exacerbations in Moderate to Severe COPD.  New England Journal of Medicine 370 (23): 2201-2210, 2014.  
89) Balfour L, Armstrong M, Holly C, Gaudet E, Aaron SD, Tasca G, Cameron W, Pakhale S.  Development and psychometric validation of a cystic fibrosis knowledge scale.  Respirology 19(8):1209-14, 2014.  
90) Alvarez G, VanDyk DD, Aaron SD, Cameron DW, et al.  TAIMA (Stop) TB: The impact of a multifaceted TB awareness and door-to-door campaign in residential areas of high risk for TB in Iqaluit, Nunavut.  PLoS ONE 9(7): e100975, 2014. doi:10.1371/journal.pone.0100975.  
91) Sadatsafavi, M, Marra C, Aaron SD, Brian S.  Incorporating external evidence in trial-based cost-effectiveness analysis: the use of resampling methods.  Trials, 15(1):201, 2014.  
92) Pakhale S, Armstrong M, Holly C, Edjoc R, Gaudet E, Aaron SD, Tasca G, Cameron W, Balfour L.  Assessment of Stigma in Patients with Cystic Fibrosis. BMC Pulmonary Medicine, 14:76, DOI: 10.1186/1471-2466-14-76, 2014.
93) Bafadhel M, Davies L, Calverley P, Aaron SD, Brightling C, Pavord I.  Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.  European Resp J, 44:789-791, 2014.  
94) Jeukens J, Boyle B, Kukavica-Ibrulj I, Ouellet M, Aaron SD, et al.  Comparative Genomics of Isolates of a Pseudomonas aeruginosa Epidemic Strain Associated with Chronic Lung Infections of Cystic Fibrosis Patients.  PLoS ONE, 9(2): e87611, 2014.   95) Tan W, Bourbeau J, Hernandez P, Chapman K, Aaron SD.  Exacerbation-Like Respiratory Symptoms in Individuals without COPD:  Results from a Population Study.  Thorax, 69(8):709-17, 2014.  
96) Stiell I, Clement C, Aaron SD, et al.  Clinical Characteristics Associated with Adverse Events in Patients with Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study.  CMAJ, 186(6):E193-204, 2014.  
97) Tan W, Bourbeau J, O’Donnell D, Aaron SD, et al. Quality Assurance of Spirometry in a Population-Based Study- Predictors of Good Outcome in Spirometry Testing.  J COPD 11: 143-152, 2014.  
98) Bourbeau J, Tan WC, Benedetti A, Aaron SD, et al.  Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD.  J of COPD, 11(2): 125-132, 2014.  
99) Gershon A, Hwee, J, Croxford R, Aaron SD, To,T.  Patient and Physician Factors Associated with Pulmonary Function Testing for Chronic Obstructive Pulmonary Disease (COPD): a Population Study.  Chest 145(2):272-281, 2014.  
100) Dettman J, Rodrigue N, Aaron SD, Kassen R.  Evolutionary genomics of epidemic and non-epidemic strains of P. aeruginosa.    PNAS, 110(52):21065-70, 2013.   

For more publications use this PubMed ID link.